AI assistant
Pfizer Ltd. — Regulatory Filings 2025
Aug 11, 2025
60507_rns_2025-08-11_f1c9b1f3-131a-41b3-a31e-e973d9180c76.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [100 x 41] intentionally omitted <==
Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274
August 11, 2025
The Corporate Relationship Dept. The Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER
Dear Sirs,
Sub: Launch of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 – Valent (PCV20)
Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that, the Company has announced the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 – Valent (PCV20) for adults in India, on August 11, 2025.
The additional details required to be disclosed, pursuant to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure A.
The press release for the said launch of PCV20 is enclosed herewith as Annexure B.
Request you to take the above on record.
Thanking you,
Yours truly, For Pfizer Limited
Prajeet Nair
Digitally signed by Prajeet Nair Date: 2025.08.11 19:04:01 +05'30'
Prajeet Nair Director – Corporate Services & Company Secretary
Encl.: A/a
CIN: L24231MH1950PLC008311 Email ID: [email protected] Website: www.pfizerltd.co.in
Annexure – A
Additional details pursuant to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
| Sr. no | Particulars | Details |
|---|---|---|
| 1. | Name of the product | Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 – Valent (PCV20). |
| 2. | Date of Launch | Available to end users on August 11, 2025. |
| 3. | Category of the product | Pneumococcal Polysaccharide Conjugate Vaccine. |
| 4. | Whether caters to Domestic Market / International Market |
Domestic Market |
| 5. | Name of the countries in which the product is launched (in case of international) |
Not Applicable |
Annexure - B
==> picture [81 x 38] intentionally omitted <==
Pfizer Launches 20-valent Pneumococcal Conjugate Vaccine (PCV20) for Adults in India, Offering Broad Protection Against Pneumococcal Disease
-
With a single dose, Pfizer’s 20-valent pneumococcal conjugate vaccine (PCV) helps protects against invasive and non-invasive pneumococcal disease caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes[1]
-
Approved for use in adults 18 years of age and older, Pfizer’s vaccine protects against more serotypes of pneumococcal disease than any other conjugate vaccine previously available in India[1]
Mumbai, August 11, 2025: Pfizer today announces the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults.[1]
Pfizer’s vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose.[1,2]
Meenakshi Nevatia, Managing Director, Pfizer Ltd., India, said , “We are excited to launch PCV20, our 20-valent pneumococcal conjugate vaccine, in India. We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunization in our country.”
Adults over 50 years of age, as well as individuals with comorbidities such as asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic kidney disease, and diabetes, face a higher risk of developing pneumococcal infections, which can result in complications, hospitalization, and even death.[3-7]
Timely immunization is critical to reducing the risk of severe illness, hospitalization, and mortality caused by pneumococcal disease. Vaccination with PCVs are considered one of the most effective public health tools for reducing the burden of pneumococcal disease.[8]
The introduction of PCV20 in India strengthens Pfizer’s longstanding commitment to preventive health and builds on 25 years of leadership in pneumococcal vaccine innovation.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply cutting-edge science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with
==> picture [81 x 38] intentionally omitted <==
our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizerltd.co.in
For media inquiries
Uma Balakrishnan M: 82913 12162 E: [email protected]
Tanisha Karunakaran M: 99879 58202 E: [email protected]
References: 1. PCV20 INDIA LPDPRV042025. 2. PCV13 INDIA LPDPRV062022. 3. Fukuda H, et al . Int J Infect Dis . 2022; 116:216-22. 4. Kunnuru S, et al . Int J Diabetes Dev Ctries.2023;1-7. 5. Koul PA, et al . Lung India. 2019;36(3):216-225. 6. Figueira-Gonçalves JM, et al. Rev Esp Quimioter. 2017:30(4):269-275. 7. Bornheimer R, et al. Open Forum Infect Dis. 2016:3(Suppl_1):1235. 8. Campling J, et al. Pneumonia (Nathan). 2019;11:4.
PP-PNR-IND-0054 | 6/8/2025
Issued in public interest by
==> picture [79 x 34] intentionally omitted <==
Pfizer Limited, The Capital, A Wing, 1802/1901, Plot No. C-70, G-Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051. India